THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTI

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,

IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS

OF SUCH JURISDICTION

Tiziana Life Sciences plc

("Tiziana" or the "Company")

Result of General Meeting

At the General Meeting of the Company held

at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue shares, to disapply pre-emption rights, replacement

of option grants and adoption of new articles of association, were duly passed.

The results of the proxy voting will be

available shortly on the Company's website, www.tizianalifesciences.com.

The person who arranged for the release

of this announcement was Tiziano Lazzaretti, Chief Financial Officer.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology

company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In

addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab is the only fully human anti-CD3

monoclonal antibody known to the company in clinical development in the world. This compound has potential application in a wide

range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS),

ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis,

where modulation of a T-cell response is desirable.

For further enquiries:

Tiziana Life Sciences plc

Liam Murray / Jo Turner